



Fig. 1/10




BEST AVAILABLE COPY

Fig. 2/10

A



B




C

	<u>Trainings set</u>	<u>Test set</u>
	Errors in crossvalidation	Test errors
MSI	6.48% (n=25, range 0-4)	6.0% (n=9, range 0-3)
MSS	1.67% (n=30, range 0-3)	1.62% (n=37, range 0-4)
All	3.85% (n=55, range 0-5)	2.48% (n=46, range 0-4)


BEST AVAILABLE COPY

Fig. 3/10



BEST AVAILABLE COPY

Fig. 4/10



BEST AVAILABLE COPY

Fig. 5/10






Fig. 6/10



BEST AVAILABLE COPY

Fig. 7/10



**BEST AVAILABLE COPY**

Fig. 8/10




Fig. 9/10





**A****B**

Fig. 10/10

**A Patients with Dukes' B Colon Cancer (No adjuvant Chemotherapy)****B Patients with Dukes' C Colon Cancer (Adjuvant Chemotherapy)****BEST AVAILABLE COPY**